Glucagon-like peptide-1 receptor (GLP-1R) agonists have been investigated for treating type 2 diabetes mellitus (T2DM) since the early 1990s because of their ability to enhance glucose-dependent insulin secretion. Here, INS is linked to type 2 diabetes mellitus.